Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shenlong Decoction granules for idiopathic pulmonary fibrosis
ChiCTR2500098632Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Liaoning University of Traditional Chinese Medicine
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Shenlong Jianji in idiopathic pulmonary fibrosis (IPF) (2 arms), sponsored by First Affiliated Hospital of Liaoning University of Traditional Chinese Medicine. Primary endpoints: Frequency of acute exacerbation of idiopathic pulmonary fibrosis and Six-minute walk test. Started Mar 2025; status: recruiting.
02
Drugs
Shenlong Jianji
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on ChiCTR2500098632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500098632.